MEDICATION OR OTHER SUBSTANCE

Similar documents
MEDICATION OR OTHER SUBSTANCE

SURGERY OR ANESTHESIA

MOST Operations Manual page 1 MEDICATION INVENTORY TABLE OF CONTENTS

MOST Operations Manual page 1 MEDICATION INVENTORY

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES

Chapter 7. Principles of Pharmacology

HCHS/SOL Medication Use Questionnaire

Brand and Generic Drugs. Educational Objectives. Absorption

Chapter 7. National EMS Education Standard Competencies (1 of 5) National EMS Education Standard Competencies (2 of 5) Principles of Pharmacology

PHARMACY BENEFITS MANAGER

Medication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

MOD 4: Medication Administration

Routes of drug administration

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

2014 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

Education Program for Prescribers and Pharmacists

Drug Prescription and Administration Record

Agency 71. Kansas Dental Board (Authorized by K.S.A and (Authorized by K.S.A and

nisterine Medications

Chapter 11 - Principles of Pharmacology

Clinical Studies in BE Evaluation of Generic Products. Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs

Review of Prescription and Other Medications and Supplements. Renée M. St. Louis, MPH

2015 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

PPP 1. Continuation, modification, and discontinuation of a medication

ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet

Dispensing and administration of emergency opioid antagonist without a

Medication Safety Presentation

Basic Pharmacology. Drugs

ATI Skills Modules Checklist for Medication Administration 2

WITH APPLICATIONS TO : ; : GENERAL AND SPECIALTY AREAS

Medication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Chloroform Codeine Ether

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1

Regulations: Adult Minimal Sedation

Agency Information Collection Activities; Submission for Office of Management and Budget

Chapter 2 is a general introduction to the drug administration

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

IN USE PRODUCT SAFETY ASSESSMENT REPORT FOR COLISTIMETHATE SODIUM

Division 1 Introduction to Advanced Prehospital Care

Chapter Goal. Learning Objectives 9/11/2012. Chapter 5. Emergency Pharmacology

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

Principles of Drug Action. Intro to Pharmacology: Principles of Courework Drug Action Intro to Pharmacology

PRSB e-discharge summary phase 2 Medications and medical devices information model

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

NEXAVAR (sorafenib tosylate) oral tablet

CMA response to TGO 92- Standards for the labels of non-prescription medicines

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

NANO 243/CENG 207 Course Use Only

FLUOXETINE 60 MG oral tablet FLUOXETINE 90 MG oral delayed release (once weekly) capsule

Lesson 5: Recording and Storage of Medication

Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY

Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY

Drug CHAPTER 2. Pharmacologic Principles. NDEG 26A Eliza Rivera-Mitu, RN, MSN. Pharmacology. Drug Names. Pharmacologic Principles. Drug Names (cont'd)

POSITION STATEMENT. Safer design of vaccines packaging and labelling

Calcium Folinate Solution for Injection

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

DDD Support Coordination Updates August 15, 2016

The Importance of Treatment Compliance. Health Education Programme targeting the Elderly on the Correct Use of Medicines (PESGG)

6. SR, XR, CR, and TR are examples of formulations. A) oral B) modified release C) repeat action D) soft gels

General Pharmacology. Henry: EMT Prehospital Care, Revised 3 rd Edition Lecture Notes Chapter 16: General Pharmacology. Case History.

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Syllabus. Allied Health Dosage Calculation Online ALH-1202

Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

DEPARTMENT OF TRANSPORTATION. National Highway Traffic Safety Administration. [Docket Number: NHTSA ]

Chapter : Sources and Bodily Effect of Drugs

ESKATA TM (hydrogen peroxide) topical solution Initial U.S. Approval: 2017

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Asthma Please complete packet and return to nurse at child s school

Chapter 11 How to state your conditions clearly to the doctor

Medicines and You: A Guide for Older Adults

miconazole and zinc oxide topical

Medication Administration and Documentation. A NC Approved CE Class offered by

Your Medicine: Be Smart. Be Safe.

201 KAR 8:550. Anesthesia and sedation.

2. The nurse must know the institution's administration procedures for the client's welfare and the nurse's legal protection.

Vitamin & Mineral Supplementation Gastric Bypass & Sleeve Gastrectomy

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Mri with baclofen pump

SAVAYSA (edoxaban tosylate) oral tablet

DRAFT PROPOSAL FOR REVISION OF GENERAL MONOGRAPHS: PARENTERAL PREPARATIONS. (July 2012) Draft for comment

UPDATE Ohana QUEST Integration Medicaid

Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form

Coventry Health Care of Georgia, Inc.

PHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004

Agreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder

AN OVERVIEW: THE MANAGEMENT OF FEVER IN CHILDREN

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]

ANNUAL FOLLOW-UP QUESTIONNAIRE FORM

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

Fundamentals of Pharmacology for Veterinary Technicians Chapter 1

LYNPARZA (olaparib) oral capsule and tablet

ESKATA (hydrogen peroxide) topical solution Initial U.S. Approval: 2017

Transcription:

Patient Safety Event Report Hospital MEDICATION OR OTHER SUBSTANCE Use this form to report any patient safety event or unsafe condition involving a substance such as a medications, biological products, nutritional products, expressed human breast milk, medical gases, or contrast media. Do not complete this form if the event involves appropriateness of therapeutic choice or decision making (e.g., physician decision to prescribe medication despite known drug-drug interaction). If the event involves a device, please also complete the Device or Medical/Surgical Supply including Health Information Technology (HIT) form. Narrative detail can be captured on the Healthcare Event Reporting Form (HERF). Highlighted fields are collected for local facility and PSO use. This information will not be forwarded to the Network of Patient Safety Databases (NPSD). 1. What type of medication/substance was involved? a. Medications 2. What type of medication? a. Prescription or over-thecounter (including herbal supplements) b. Compounded preparations c. Investigational drugs d. Unknown 3. Please list all ingredients: b. Biological products 4. What type of biological product? a. Vaccines b. Other biological products (e.g., thrombolytic) 5. What was the lot number of the vaccine? LOT NUMBER c. Nutritional products d. Expressed human breast milk e. Medical gases (e.g., oxygen, nitrogen, nitrous oxide) f. Contrast media 6. What type of nutritional product? a. Dietary supplements (other than vitamins or minerals) b. Vitamins or minerals c. Enteral nutritional products, including infant formula d. Parenteral nutritional products e. Other: PLEASE SPECIFY g. Radiopharmaceuticals h. Patient food (not suspected in drug-food interactions) i. Drug-drug, drug-food, or adverse drug reaction as a result of a prescription and/or administration of a drug and/or food prior to admission j. Other substance: PLEASE SPECIFY STOP This form is complete. Page 1 of 5

7. Which of the following best characterizes the event? a. Incorrect action (process failure or error) (e.g., such as administering overdose or incorrect medication) b. Unsafe condition Event ID: ANSWER QUESTIONS 17-25 c. Adverse reaction in patient to the administered substance without any apparent incorrect action d. Unknown STOP This form is complete. 8. What was the incorrect action? CHECK ALL THAT APPLY: a. Incorrect patient b. Incorrect medication/substance c. Incorrect dose(s) d. Incorrect route of administration 9. Which best describes the incorrect dose(s)? a. Overdose b. Underdose c. Missed or omitted dose d. Extra dose e. Unknown e. Incorrect timing 10. Which best describes the incorrect timing? a. Too early b. Too late f. Incorrect rate 11. Which best describes the incorrect rate? a. Too quickly b. Too slowly g. Incorrect duration of administration or course of therapy h. Incorrect dosage form (e.g., sustained release instead of immediate release) i. Incorrect strength or concentration j. Incorrect preparation, including inappropriate cutting of tablets, error in compounding, mixing, etc. k. Expired or deteriorated medication/substance l. Medication/substance that is known to be an allergen to the patient m. Medication/substance that is known to be contraindicated for the patient 12. Which best describes the incorrect strength or concentration? a. Too high b. Too low 13. What was the expiration date? / / MM DD YYYY 14. Was there a documented history of allergies or sensitivities to the medication/substance administered? 15. What was the contraindication (potential or actual interaction)? a. Drug-drug b. Drug-food c. Drug-disease d. Other: PLEASE SPECIFY n. Incorrect patient/family action (e.g., self-administration error) o. Other: PLEASE SPECIFY _ Page 2 of 5

16. At what stage in the process did the event originate, regardless of the stage at which it was discovered? a. Purchasing b. Storing c. Prescribing/ordering d. Transcribing e. Preparing f. Dispensing g. Administering h. Monitoring i. Unknown j. Other: PLEASE SPECIFY QUESTIONS 17-27 DO NOT APPLY TO COMPOUNDED PREPARATION OR EXPRESSED HUMAN BREAST MILK FOR AN INCIDENT, ANSWER QUESTIONS 17-27 FOR A NEAR MISS, ANSWER QUESTIONS 17-26 FOR AN UNSAFE CONDITION, ANSWER QUESTIONS 17-25 Page 3 of 5

Please provide the following medication details for any medications or other substances directly involved in the event. 17. Generic name or investigational drug name 18. Ingredient RXCUI 19. Brand name (if known) 20. Brand name RXCUI 21. Manufacturer 22. Strength or concentration of product 1 2 3 4 5 23. Clinical drug component RXCUI 24. Dosage form of product 25. Dose form RXCUI 26. Was this medication/ substance prescribed for this patient? 27. Was this medication / substance given to this patient? 1 2 3 4 5 IF THIS EVENT DID NOT INVOLVE AN INCORRECT ROUTE OF ADMINISTRATION STOP This form is complete. IF THE EVENT INVOLVED AN INCORRECT ROUTE OF ADMINISTRATION, ANSWER QUESTIONS 28-29 Page 4 of 5

28. What was the intended route of administration? a. Cutaneous, topical application, including ointment, spray, patch b. Subcutaneous c. Ophthalmic d. Oral, including sublingual or buccal e. Otic f. Nasal g. Inhalation h. Intravenous i. Intramuscular j. Intrathecal k. Epidural l. Gastric m. Rectal n. Vaginal o. Unknown p. Other: PLEASE SPECIFY 29. What was the actual route of administration (attempted or completed)? a. Cutaneous, topical application, including ointment, spray, patch b. Subcutaneous c. Ophthalmic d. Oral, including sublingual or buccal e. Otic f. Nasal g. Inhalation h. Intravenous i. Intramuscular j. Intrathecal k. Epidural l. Gastric m. Rectal n. Vaginal o. Unknown p. Other: PLEASE SPECIFY Thank you for completing these questions. OMB No. 0935-0143 Exp. Date 12/31/2017 Public reporting burden for the collection of information is estimated to average 10 minutes per response. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: AHRQ Reports Clearance Officer, Attention: PRA, Paperwork Reduction Project (0935-0143) AHRQ, 5600 Fishers Lane, # 07W41A, Rockville, MD 20857. Page 5 of 5